SGLT2抑制剂与前列腺癌激素治疗患者的临床结局
IMPORTANCE: While preliminary evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors for diabetes may have antitumorigenic effects, their potential benefits in prostate cancer remain unexplored.…
要点
- SGLT2抑制剂使用与ADT失败风险降低相关(HR 0.63,95%CI 0.41-0.95)。
- SGLT2抑制剂使用与下一代激素药物失败风险降低相关(HR 0.44,95%CI 0.20-0.97)。
- 二甲双胍单药与疾病进展无关,但与总生存改善相关(HR 0.59,95%CI 0.42-0.83)。
核心结论
- 在接受激素治疗的前列腺癌患者中,SGLT2抑制剂使用与激素治疗失败延迟相关,提示降糖之外的潜在肿瘤学获益。
研究设计与样本
- 暴露定义为激素治疗期间启动并维持至少1个月的SGLT2抑制剂使用(主要为达格列净和恩格列净),对照为非使用者。
主要发现
- 敏感性分析在不同对照亚组中证实上述结果的稳健性。
- 达格列净与恩格列净之间未观察到统计学显著的结局差异。
临床怎么用
- 对于合并糖尿病且正在接受ADT的前列腺癌患者,选用SGLT2抑制剂可能同时带来降糖与延迟激素治疗失败的潜在获益。
- 该证据来自观察性目标试验模拟,不能直接改变临床用药指征,需结合患者代谢状况个体化决策。
局限性
- 研究为基于电子健康记录的观察性目标试验模拟,可能存在未测量混杂。
- SGLT2抑制剂暴露定义要求维持至少1个月,可能遗漏短期用药或影响因果推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: While preliminary evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors for diabetes may have antitumorigenic effects, their potential benefits in prostate cancer remain unexplored. Understanding their association with outcomes among patients undergoing hormone therapy could inform future adjunct treatment strategies. OBJECTIVE: To evaluate whether the use of SGLT2 inhibitors is associated with clinical outcomes in patients with prostate cancer receiving hormone therapy. DESIGN, SETTING, AND PARTICIPANTS: This population-based, sequential target trial emulation of monthly cohorts used territory-wide electronic health records (January 1, 1993, to April 30, 2025) from the Hong Kong Hospital Authority, covering a population of approximately 7.5 million. Adult men diagnosed with prostate cancer who initiated androgen deprivation therapy (ADT) were included. Follow-up extended through April 2025, and data were analyzed from June to October 2025. EXPOSURES: Use of SGLT2 inhibitors (primarily dapagliflozin and empagliflozin) initiated during hormone therapy and maintained for at least 1 month. Comparator groups included nonusers of SGLT2 inhibitors. MAIN OUTCOMES AND MEASURES: The primary outcome was time to ADT failure. Secondary outcomes include time to next-generation hormonal agent failure, disease-specific survival, and overall survival. Both intention-to-treat and per-protocol analyses were conducted using complementary log-log model regression to provide the hazard ratio (HR) estimate. RESULTS: Among 14 223 eligible patients (median [IQR] age at enrollment, 74 [68-80] years) with a median follow-up of 66 months (95% CI, 65-67 months), intention-to-treat SGLT2 inhibitor use was associated with reduced risk of ADT failure (HR, 0.63; 95% CI, 0.41-0.95; P = .03) and next-generation hormonal agent failure (HR, 0.44; 95% CI, 0.20-0.97; P = .04). Sensitivity analyses confirmed robustness of these findings across different comparator subgroups. Metformin monotherapy was not associated with disease progression but was associated with improved overall survival (HR, 0.59; 95% CI, 0.42-0.83; P = .002). No statistically significant outcome differences were observed between dapagliflozin and empagliflozin. CONCLUSIONS AND RELEVANCE: In this cohort study with a target trial emulation design, SGLT2 inhibitor use was associated with delayed hormone therapy failure in patients with prostate cancer, suggesting a potential oncologic benefit beyond glucose lowering. These findings support the potential of SGLT2 inhibitors in treatment for prostate cancer.
引用
- Shi R, Zhan Y, Ma R, et al. Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy. JAMA Oncol. 2026. PMID: 41505116. doi:10.1001/jamaoncol.2025.5869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。